Randomized Phase III Trial of Bortezomib, LENalidomide and Dexamethasone (VRd) Versus Carfilzomib, Lenalidomide and Dexamethasone (CRd) Followed by Limited or Indefinite DURation Lenalidomide MaintenANCE in Patients with Newly Diagnosed Symptomatic Multiple Myeloma (ENDURANCE)
The purpose of the study is to compare the effects on your multiple myeloma, good and/or bad, of a combination of the drugs carfilzomib, lenalidomide and dexamethasone with another combination of the drugs bortezomib, lenalidomide and dexamethasone, to find out which is better.
After that part of the study, researchers want to see if it is better to continue lenalidomide until your myeloma relapses or limit it for a defined period of 2 years.
- At least 18 years old
- Have symptomatic multiple myeloma
- Must have received no more than one cycle (4 weeks or less) of prior chemotherapy and no more than 160mg of prior dexamethasone (or equivalent dose of prednisone) for treatment of symptomatic myeloma
- No prior treatment with lenalidomide, bortezomib or carfilzomib
18 - 99
Healthy Volunteers Needed
Duration of Participation
You will be in the study until one of the following happens:
• Your disease gets worse
• You no longer want to continue with treatment
• You begin another treatment
• You experience serious side-effects
After you have finished your designated regimen, the investigator will ask you to visit the office for follow-up exams for at least 15 years.
Clinical Trials Information Line
ECOG-ACRIN Cancer Research Group and the National Cancer Institute